Cholesterol
In clinical developmentAlso known as Cholest-5-en-3beta-ol.
Recent clinical, regulatory, research and industry developments relating to this drug.
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol
Millions may be getting the wrong cholesterol test
How long-term dietary cholesterol can slow down its own clearance by liver cells
Drug Targets LDL Receptor Pathway to Control Cholesterol
Dietary cholesterol activates a Ral-dependent pathway driving LDLR turnover
Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
Macrophage-mediated myelin recycling fuels brain cancer malignancy.
Cholesterol imbalance and neurotransmission defects in neurodegeneration.
The IRG1-itaconate axis protects from cholesterol-induced inflammation and atherosclerosis.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Frontiers in endocrinology2
- International journal of molecular sciences2
- Nature2
- Annals of medicine1
- Cell1
- Endocrine reviews1
- Agrawal R1
- Akkari L1
- Al Khleifat A1
- Al-Chalabi A1
- Ali Moussa HY1
- Amadori L1
- Amouyel P1
- Andersen PM1
- School of Medicine3
- Academic Medical Center2
- Institute of Human Genetics2
- Stanley Center for Psychiatric Research2
- University Hospital Schleswig-Holstein2
- 'Dino Ferrari' Center1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 10 of the same disease areas as Cholesterol in the shared literature.
Studied across 10 of the same disease areas as Cholesterol in the shared literature.
Studied across 10 of the same disease areas as Cholesterol in the shared literature.
Studied across 7 of the same disease areas as Cholesterol in the shared literature.
Studied across 5 of the same disease areas as Cholesterol in the shared literature.
Studied across 5 of the same disease areas as Cholesterol in the shared literature.
Studied across 5 of the same disease areas as Cholesterol in the shared literature.
Studied across 4 of the same disease areas as Cholesterol in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials